Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DW5121
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212
Details : DW5121 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Bronchitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 30, 2025
Lead Product(s) : DW5121
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DW1026C1
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
Details : DW1026C1 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 21, 2025
Lead Product(s) : DW1026C1
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Merigolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Recipient : Tiumbio
Deal Size : Inapplicable
Deal Type : Inapplicable
TiumBio and Daewon Complete Phase 2 Merigolix Trial for Fibroids
Details : TU2670 (merigolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist, being investigated for uterine fibroids.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 07, 2025
Lead Product(s) : Merigolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Recipient : Tiumbio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DW5221
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial to Evaluate the Pharmacokinetic Characteristics of DW5221 and DW5221-R
Details : DW5221 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 28, 2023
Lead Product(s) : DW5221
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A
Details : Ezetimibe is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2023
Lead Product(s) : Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DWKH
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial to Evaluate the Efficacy and Safety of DWKH
Details : DWKH is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Respiratory Tract Infections.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 13, 2023
Lead Product(s) : DWKH
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Choline Fenofibrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Recipient : Seoul National University Bundang Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Choline Fenofibrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dyslipidemias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 09, 2022
Lead Product(s) : Choline Fenofibrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Recipient : Seoul National University Bundang Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DW1809
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809
Details : DW1809 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 31, 2022
Lead Product(s) : DW1809
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DW1809-T2
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2
Details : DW1809-T2 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 31, 2022
Lead Product(s) : DW1809-T2
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DW1903
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient
Details : DW1903 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastritis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 20, 2021
Lead Product(s) : DW1903
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable